Literature DB >> 34915975

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.

Lin T Brandal1, Emily MacDonald1, Lamprini Veneti1, Tine Ravlo2, Heidi Lange1, Umaer Naseer1, Siri Feruglio1, Karoline Bragstad1, Olav Hungnes1, Liz E Ødeskaug1, Frode Hagen2, Kristian E Hanch-Hansen2, Andreas Lind3, Sara Viksmoen Watle1, Arne M Taxt1, Mia Johansen1, Line Vold1, Preben Aavitsland1, Karin Nygård1, Elisabeth H Madslien1.   

Abstract

In late November 2021, an outbreak of Omicron SARS-CoV-2 following a Christmas party with 117 attendees was detected in Oslo, Norway. We observed an attack rate of 74% and most cases developed symptoms. As at 13 December, none have been hospitalised. Most participants were 30-50 years old. Ninety-six percent of them were fully vaccinated. These findings corroborate reports that the Omicron variant may be more transmissible, and that vaccination may be less effective in preventing infection compared with Delta.

Entities:  

Keywords:  COVID-19; Omicron; SARS-CoV-2; cohort-study; outbreak investigation

Mesh:

Year:  2021        PMID: 34915975      PMCID: PMC8728491          DOI: 10.2807/1560-7917.ES.2021.26.50.2101147

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


On 30 November 2021 the Norwegian Institute of Public Health (NIPH) was notified by a local laboratory in Oslo of a coronavirus disease (COVID-19) case with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) (Phylogenetic Assignment of Named Global Outbreak Lineages (Pangolin) designation B.1.1.529 BA.1) infection [1]. The laboratory provided information that the case was likely exposed at a company Christmas party held on 26 November 2021 and that one of the attendees had returned from South Africa on 24 November 2021. The novel SARS-CoV-2 variant Omicron was first detected in samples collected mid-November 2021 in Botswana and South Africa [2]. Here we describe the outbreak and preliminary findings from our epidemiological investigations.

Setting

The closed event was held in a separate room (ca 145 m2) in a restaurant in Oslo from 18:00 to 22:30, after which the venue was opened to the public from 22:30 to 03:00. A pre-party had been arranged for the Christmas party attendees at a separate venue, after which they were transported by private buses to the restaurant. Although there were no restrictions in place for events at the time in Norway, all attendees of the party were reported to be fully vaccinated and had been asked by the organiser to perform a rapid antigen self-test. For other guests visiting the venue and employees working at the restaurant, there were no requirements for vaccination, COVID-19 testing, face-mask use or COVID certificate, and a guest list was not maintained. Attendees of the party mingled at the venue before and after dinner, following which the bar and dance area was opened to the public. After detection of the outbreak on 30 November, all attendees at the party were requested by the municipality doctor in Oslo to self-quarantine at home for 10 days and to immediately take a PCR test. Those who tested positive were required to remain in isolation for at least 7 days [3]. In addition, a public message was released on 1 December asking anyone who had been at the venue from 22:30 on 26 November to 03:00 on 27 November to get tested by PCR as soon as possible, regardless of symptoms.

Outbreak investigation

On 1 December, following a targeted exploration because of recent travel to South Africa, the suspected index case was verified to be infected with the SARS-CoV-2 Omicron VOC by whole genome sequencing (WGS) and the municipality of Oslo and the NIPH initiated an outbreak investigation. We conducted a cohort study to describe the outbreak and symptoms of infection in order to increase knowledge about the Omicron variant and to better target control measures. The cohort was defined as all attendees at the party on 26 November 2021 (n = 117). A confirmed case was defined as a person who attended the party on 26 November 2021 and tested positive for the SARS-CoV-2 Omicron variant up to 13 December, through either PCR variant screening and/or WGS. A probable case was defined as a person who attended the party on 26 November and tested positive for SARS-CoV-2 by PCR. Contact details for the attendees were obtained from the organisers. Participants were interviewed by a team at the NIPH by telephone between 4 and 6 December, using a standardised questionnaire to collect demographic and clinical information, including date of onset and duration of a predefined list of symptoms, where relevant.

Laboratory analysis

All SARS-CoV-2 positive samples from the party attendees were screened for SARS-CoV-2 virus variants in different local laboratories, mostly by S-gene 69/70 deletion or single-nucleotide polymorphism (SNP) targeted PCR for different other markers that were suited to differentiate Omicron from the hitherto completely predominant Delta variant. Available samples were also subjected to WGS. Whole genome sequences were submitted to Global Initiative on Sharing All Influenza Data (GISAID). Suspected outbreak index: EPI_ISL_7040235.

Demographic and clinical information

In total, 111 out of 117 attendees (95%) participated in the interviews. Respondents had an average age of 39 years (SD: 9.2; median: 38; range: 26–68) and 48 (43%) of them were women. Most respondents (n = 107; 96%) were fully vaccinated. Eighty-nine percent of the respondents (n = 99) had received two doses of mRNA vaccines. None reported having received a booster dose. All respondents reported having a negative rapid antigen self-test taken at home or PCR within 1–2 days before attending the event. Eight (7%) respondents had previously had COVID-19, but none in the previous 4 months, according to information gathered through the interviews. Of the 111 respondents, 66 (59%) were confirmed cases (26 based on WGS and 40 based on PCR VOC screening) and 15 (14%) were probable cases (PCR-positive only). One PCR-positive attendee was confirmed to be infected with SARS-CoV-2 Delta variant (Pango lineage B.1.617.2), and subsequently excluded from further analysis. The total attack rate for the Omicron variant was 74% (81/110) (Figure). The cases had an average age of 38 years (SD: 8.6; median 36, range: 26–61) and 35 (43%) were women. The remaining 29 attendees did not have a positive PCR result by 13 December 2021.
Figure

Distribution of COVID-19 cases infected with the SARS-CoV-2 Omicron variant by date of symptom onset and case classification, after attending Christmas party, Oslo, Norway, November−December 2021 (n = 81)

Distribution of COVID-19 cases infected with the SARS-CoV-2 Omicron variant by date of symptom onset and case classification, after attending Christmas party, Oslo, Norway, November−December 2021 (n = 81) COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. a One of the confirmed cases was asymptomatic and not presented in the epicurve. b Returned from travel to Africa or Europe less than 1 week before the party. None of them reported symptoms in the period before the party. Assuming exposure occurred at the party, the incubation period for symptomatic cases ranged from 0 to 8 days with a median of 3 days (interquartile range: 3−4). One case was asymptomatic and 74 (91%) reported at least three symptoms. Among the 81 cases, the most common symptoms were cough (83%), followed by runny/stuffy nose (78%), fatigue/lethargy (74%), sore throat (72%), headache (68%) and fever (54%) (Table). When asked to grade the severity of symptoms on a scale from 1 (no symptoms) to 5 (significant symptoms), 42% (33/79) reported level 3 symptoms, whereas 11% (9/79) reported level 4 symptoms. None of the cases required hospitalisation up to 13 December 2021.
Table

Symptoms reported between 19 November and 3 December, by case status, in SARS-CoV-2 Omicron variant outbreak at Christmas party, Oslo, 26 November 2021 (n = 110)

SymptomNon-cases(n = 29)Cases(n = 81)a
nbMedian duration in days (IQR)cn%Median duration in days (IQR)c
Cough93 (2–6)67834 (3–5)
Runny/stuffy nose104 (2–12)63784 (2–5)
Fatigue/lethargy63 (2–4)60744 (2–5)
Sore throat112.5 (1–6)58723 (2–5)
Headache< 555682 (2–4)
Muscle pain< 547582.5 (2–4)
Fever< 544542 (2–3)
Sneezing104 (2–9)35433 (2–4)
Reduced smell< 510122 (2–3)
Reduced appetite< 527333 (2–5)
Heavy breathing10122 (1–5)
Reduced taste< 519232.5 (2–4)
Abdominal pain< 5562 (1–3)
Any of the above listed symptoms194 (3–7)80996 (5–8)

IQR: interquartile range; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

a One confirmed case was asymptomatic and therefore not included.

b Symptoms reported by less than five participants are reported as < 5.

c Duration of symptoms might have been underestimated for some participants if the symptoms were still present after the day they were interviewed. Five non-cases and 62 cases reported still having symptoms on the day they were interviewed.

IQR: interquartile range; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. a One confirmed case was asymptomatic and therefore not included. b Symptoms reported by less than five participants are reported as < 5. c Duration of symptoms might have been underestimated for some participants if the symptoms were still present after the day they were interviewed. Five non-cases and 62 cases reported still having symptoms on the day they were interviewed. Duration of symptoms cannot be estimated accurately since 62 (78%) of the 80 symptomatic cases were still experiencing symptoms at the time of the interviews. Seven cases reported symptoms consistent with COVID-19 within 2 weeks prior the party, with less than five reporting onset more than 1 week before the party. Seven cases reported recent (≤ 7days) travel abroad, three in Africa and four in Europe. None of these cases reported symptoms in the period before the party. Almost all (n = 104; 95%) of the 110 respondents reported being at work the week before the party and 87% (n = 96) shared offices.

Vaccination status

Most of the cases (n = 79; 98%) and non-cases (n = 27; 93%) were fully vaccinated with a median time since receiving the last vaccine dose of 79 days for cases and 87 days for non-cases (no statistically significant difference, Wilcoxon rank-sum p = 0.48). Among cases who had received two vaccine doses, 55% (41/75) received Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer, Mainz, Germany/New York, United States (US)) whereas 23% (17/75) received Spikewax (mRNA-1273, Moderna, Cambridge, US). Among the 25 non-cases who had received two doses, seven received Comirnaty whereas 12 received Spikewax. In addition, during the investigation and as at 13 December, we detected nearly 70 other guests that were likely infected at the venue, and the Omicron variant was detected in 53 of these through PCR variant screening or sequencing.

Discussion

Our preliminary investigation of the first outbreak in Norway with the Omicron VOC supports the notion that this SARS-CoV-2 variant is highly transmissible even among fully vaccinated people. Given the limited knowledge on transmissibility, severity and immune escape for this VOC [2,4], it will be important to compare outbreaks in different contexts. Superspreading events have been widely reported linked to other variants [2,5-8]. Previous outbreaks caused by the SARS-CoV-2 Delta variant have also been reported in Norway among highly vaccinated populations (data not shown). In the outbreak described here, the high attack rate with symptomatic infection was likely exacerbated by the context and setting of the outbreak (indoor location, long exposure time, crowding, and the need to talk loudly) [6,9]. Some transmission may have occurred among colleagues in the workplace or at the pre-party as some of the attendees had symptoms prior to the party. We can also not exclude that there may have been multiple virus introductions, although all attendees reported a negative test result before the party. This will further be explored when whole genome sequencing results are available for all confirmed cases. However, our experience with this outbreak corroborates reports from other countries that the Omicron variant may be more transmissible and that vaccination may be less effective to prevent infection than for the Delta variant [4,10-13]. It is not possible to draw any conclusions regarding effectiveness of different vaccine types against infection with Omicron based on this single outbreak. Assuming attendees were infected at the party, we observed a median incubation period of 3 days, which is short compared with previous reports for Delta and other previously circulating non-Delta SARS-CoV-2 (4.3 and 5.0 days, respectively) [14]. Furthermore, almost all cases developed at least one symptom, and more than half (54%) reported fever. Attendees will be interviewed at least once more in the coming days in order to follow up on symptoms, duration and secondary transmission to household members. The outbreak was rapidly detected due to the comprehensive and timely test capacity and surveillance in Norway. The combination of rapid detection with contact tracing, isolation and quarantine measures, was probably able to slow down the spread of the outbreak in the short term, but it is unlikely that the implemented control measures will have interrupted the spread of the Omicron VOC. Norway does not currently apply the European Union Digital COVID Certificate for entry to venues. We believe that this outbreak would probably not have been prevented even if such a system were in place, given that nearly all participants had received at least one dose of the COVID-19 vaccine and the majority were fully vaccinated and tested by antigen test before the event. However, we cannot exclude that vaccination has reduced the risk of serious illness; no hospitalisations were reported among cases until 13 December, and until more information is available, vaccination, including providing booster doses to risk groups, will continue to be a key control measure. In addition, it is important to further strengthen communication about the need to stay at home when experiencing symptoms, regardless of the cause. In light of the rapidly evolving situation, Norway has implemented increasingly stringent control measures since 2 December, because of both stress on the healthcare system due to the Delta variant and the rapid spread of the Omicron VOC. As at 16 December, these measures include restrictions of public and private events, such as reduction of group sizes, requirements for working from home and a ban on serving alcohol in restaurants and bars for an initial period of 4 weeks [15].

Conclusions

The preliminary results of our outbreak investigation indicate that the SARS-CoV-2 Omicron VOC is highly transmissible among fully vaccinated young and middle-aged adults. However, given the specific context of the outbreak in a high-risk setting for transmission, the findings must be interpreted with caution. The investigation is continuing to determine the full spectrum of illness and its duration, the risk factors for infection and the extent of secondary transmission. More systematic surveillance and research is needed in order to determine the epidemiological and clinical characteristics of the Omicron variant and the appropriate control measures for managing outbreaks.
  7 in total

Review 1.  Catch me if you can: superspreading of COVID-19.

Authors:  Seema S Lakdawala; Vineet D Menachery
Journal:  Trends Microbiol       Date:  2021-05-11       Impact factor: 17.079

2.  Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak.

Authors:  Tsuyoshi Sekizuka; Kentaro Itokawa; Tsutomu Kageyama; Shinji Saito; Ikuyo Takayama; Hideki Asanuma; Naganori Nao; Rina Tanaka; Masanori Hashino; Takuri Takahashi; Hajime Kamiya; Takuya Yamagishi; Kensaku Kakimoto; Motoi Suzuki; Hideki Hasegawa; Takaji Wakita; Makoto Kuroda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-28       Impact factor: 11.205

3.  Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events.

Authors:  Jacob E Lemieux; Katherine J Siddle; Glen R Gallagher; Lawrence C Madoff; Sandra Smole; Virginia M Pierce; Eric Rosenberg; Pardis C Sabeti; Daniel J Park; Bronwyn L MacInnis; Bennett M Shaw; Christine Loreth; Stephen F Schaffner; Adrianne Gladden-Young; Gordon Adams; Timelia Fink; Christopher H Tomkins-Tinch; Lydia A Krasilnikova; Katherine C DeRuff; Melissa Rudy; Matthew R Bauer; Kim A Lagerborg; Erica Normandin; Sinéad B Chapman; Steven K Reilly; Melis N Anahtar; Aaron E Lin; Amber Carter; Cameron Myhrvold; Molly E Kemball; Sushma Chaluvadi; Caroline Cusick; Katelyn Flowers; Anna Neumann; Felecia Cerrato; Maha Farhat; Damien Slater; Jason B Harris; John A Branda; David Hooper; Jessie M Gaeta; Travis P Baggett; James O'Connell; Andreas Gnirke; Tami D Lieberman; Anthony Philippakis; Meagan Burns; Catherine M Brown; Jeremy Luban; Edward T Ryan; Sarah E Turbett; Regina C LaRocque; William P Hanage
Journal:  Science       Date:  2020-12-10       Impact factor: 47.728

4.  Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France.

Authors:  Rebecca Grant; Tiffany Charmet; Laura Schaeffer; Simon Galmiche; Yoann Madec; Cassandre Von Platen; Olivia Chény; Faïza Omar; Christophe David; Alexandra Rogoff; Juliette Paireau; Simon Cauchemez; Fabrice Carrat; Alexandra Septfons; Daniel Levy-Bruhl; Alexandra Mailles; Arnaud Fontanet
Journal:  Lancet Reg Health Eur       Date:  2021-11-26

5.  SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-12-17       Impact factor: 17.586

6.  Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.

Authors:  Catherine M Brown; Johanna Vostok; Hillary Johnson; Meagan Burns; Radhika Gharpure; Samira Sami; Rebecca T Sabo; Noemi Hall; Anne Foreman; Petra L Schubert; Glen R Gallagher; Timelia Fink; Lawrence C Madoff; Stacey B Gabriel; Bronwyn MacInnis; Daniel J Park; Katherine J Siddle; Vaira Harik; Deirdre Arvidson; Taylor Brock-Fisher; Molly Dunn; Amanda Kearns; A Scott Laney
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-08-06       Impact factor: 17.586

  7 in total
  82 in total

1.  Use of a Screening Protocol to Identify Asymptomatic COVID-19 in a Free Community Health Clinic in Shelby County, Alabama, October 2020-February 2021.

Authors:  James R Kilgore; Justin R Johnston; Barbara Van Der Pol; Peng Li; Mark Wilson; William Curry; Cynthia Selleck
Journal:  Public Health Rep       Date:  2022-07-21       Impact factor: 3.117

2.  COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).

Authors:  Wan Yang; Jeffrey L Shaman
Journal:  Elife       Date:  2022-08-09       Impact factor: 8.713

3.  Modeling pandemic to endemic patterns of SARS-CoV-2 transmission using parameters estimated from animal model data.

Authors:  Sarah Mullin; Brent Vander Wyk; Jennifer L Asher; Susan R Compton; Heather G Allore; Caroline J Zeiss
Journal:  PNAS Nexus       Date:  2022-07-01

4.  Modeling Cross-Regional Transmission and Assessing the Effectiveness of Restricting Inter-Regional Population Movements in Controlling COVID-19 - Xi'an City, Shaanxi Province, China, 2021.

Authors:  Tianlong Yang; Yao Wang; Nankun Liu; Guzainuer Abudurusuli; Shiting Yang; Shanshan Yu; Weikang Liu; Xuecheng Yin; Tianmu Chen
Journal:  China CDC Wkly       Date:  2022-08-05

5.  COVID-19 patients at referral to hospital during the first peak of disease: Common clinical findings including myalgia and fatigue.

Authors:  Amin Honarmand; Fateme Sheybani; Elahe Aflatoonian; Amin Saberinia
Journal:  Eur J Transl Myol       Date:  2022-08-12

6.  Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation.

Authors:  Chad R Wells; Abhishek Pandey; Seyed M Moghadas; Burton H Singer; Gary Krieger; Richard J L Heron; David E Turner; Justin P Abshire; Kimberly M Phillips; A Michael Donoghue; Alison P Galvani; Jeffrey P Townsend
Journal:  Commun Med (Lond)       Date:  2022-07-09

7.  SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.

Authors:  Yao Ma; Ye Wang; Chunhong Dong; Gilbert X Gonzalez; Wandi Zhu; Joo Kim; Lai Wei; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Small       Date:  2022-05-23       Impact factor: 15.153

8.  Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations.

Authors:  Brittany A Petros; Jacquelyn Turcinovic; Nicole L Welch; Laura F White; Eric D Kolaczyk; Matthew R Bauer; Michael Cleary; Sabrina T Dobbins; Lynn Doucette-Stamm; Mitch Gore; Parvathy Nair; Tien G Nguyen; Scott Rose; Bradford P Taylor; Daniel Tsang; Erik Wendlandt; Michele Hope; Judy T Platt; Karen R Jacobson; Tara Bouton; Seyho Yune; Jared R Auclair; Lena Landaverde; Catherine M Klapperich; Davidson H Hamer; William P Hanage; Bronwyn L MacInnis; Pardis C Sabeti; John H Connor; Michael Springer
Journal:  Clin Infect Dis       Date:  2022-05-25       Impact factor: 20.999

9.  Concerns on the Effectiveness of Current COVID-19 Vaccines.

Authors:  Xingguang Li
Journal:  Front Microbiol       Date:  2022-06-06       Impact factor: 6.064

Review 10.  Risk of SARS-CoV-2 in a car cabin assessed through 3D CFD simulations.

Authors:  Fausto Arpino; Giorgio Grossi; Gino Cortellessa; Alex Mikszewski; Lidia Morawska; Giorgio Buonanno; Luca Stabile
Journal:  Indoor Air       Date:  2022-03       Impact factor: 6.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.